Retatrutide Phase 3 Trials Status 2026

TRIUMPH-4 Update: Obesity + Knee OA Readout

TRIUMPH-4 is the first trial in the TRIUMPH program to report Phase 3 results. The trial enrolled participants with obesity and knee osteoarthritis — a population where weight loss directly addresses the mechanical and inflammatory drivers of joint disease. For broader cross-asset context, see how this slots into the obesity drug approval tracker.

The headline numbers: participants receiving retatrutide achieved a mean 28.7% body weight loss, the highest figure reported in any retatrutide trial to date. This exceeded the 24.2% seen in Phase 2 at 48 weeks, likely due to the longer treatment duration and the specific population studied. The trial included a retatrutide 9 mg arm, which was evaluated for both weight management and osteoarthritis pain relief.

Beyond weight loss, TRIUMPH-4 demonstrated clinically meaningful improvements in osteoarthritis pain, with reductions in pain score measured using the WOMAC index, a validated instrument for assessing osteoarthritis pain and function. The combination of substantial weight reduction and direct pain relief makes this a significant dataset for Lilly’s regulatory strategy. For the broader regulatory view, see the retatrutide status page.

Background on Lilly’s Triple Agonist Retatrutide

Retatrutide, developed by Eli Lilly and Company, represents a major innovation in the field of obesity and metabolic disease research. As a triple hormone receptor agonist, retatrutide uniquely targets the GIP, GLP-1, and glucagon receptors simultaneously — a mechanism that sets it apart from existing therapies like semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP dual agonist). For a head-to-head breakdown across the class, see retatrutide vs tirzepatide vs CagriSema.

The triple agonist mechanism enables retatrutide to deliver significant weight loss by enhancing satiety, reducing caloric intake, and increasing metabolic rate. In clinical trials, this has translated into unprecedented reductions in body weight, particularly in adults with obesity and related conditions such as knee osteoarthritis. Beyond weight loss, retatrutide’s broad metabolic effects extend to improvements in cardiovascular and renal outcomes — key considerations for participants with established cardiovascular disease or at elevated risk.

Eli Lilly and Company’s development strategy for retatrutide reflects a holistic vision for obesity research, targeting not only excess body weight but also the downstream complications of metabolic dysfunction. Early data also suggest benefits for fatty liver disease, further underscoring retatrutide’s potential as a comprehensive investigational compound. As the TRIUMPH clinical trial program progresses, retatrutide is positioned to redefine standards for delivering significant weight loss and improving long-term metabolic outcomes — you can also compare it head-to-head with the oral candidate in retatrutide vs orforglipron.

What is Retatrutide Phase 3 Trials Status in 2026?

Retatrutide Phase 3 development remains active, with TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRIUMPH-4, and TRANSCEND-T2D-1 topline datasets now public and additional studies still underway. Lilly continues to describe retatrutide as investigational and not FDA approved.

TRIUMPH-1 enrolled 2,339 adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related comorbidity, excluding type 2 diabetes, with a mean baseline BMI of 40.0 and baseline weight of 112.7 kg. The companion retatrutide dosage guide covers the research-trial titration schedule used across these arms.

Eli Lilly reported positive topline results on May 21, 2026. In this randomized, double-blind, placebo-controlled trial, all three doses met the primary and key secondary endpoints. At 80 weeks, mean body weight reduction was 19.0% at 4 mg (47.2 lb), 25.9% at 9 mg (64.4 lb), and 28.3% at 12 mg (70.3 lb), versus 2.2% on placebo. On the 12 mg dose, 45.3% of participants achieved ≥30% weight loss and 65.3% reached a BMI under 30 — a magnitude often associated with bariatric surgery.

A prespecified blinded extension in completers with a baseline BMI ≥35, maintained on 12 mg to the maximum tolerated dose, showed continued reduction to 30.3% mean weight loss (85.0 lb) at 104 weeks without an apparent plateau. Weight loss was accompanied by cardiometabolic improvements, including a 24.1 cm waist-circumference reduction and favourable changes in non-HDL cholesterol, triglycerides, systolic blood pressure, and hs-CRP. Adverse events were the gastrointestinal effects typical of the incretin class; treatment discontinuation rose with dose (4.1%, 6.9%, and 11.3% vs 4.9% on placebo). Dysesthesia was reported in up to 12.5% on 12 mg, and urinary tract infections occurred in 7.5%, 8.8%, and 8.4% across the 4, 9, and 12 mg groups versus 5.3% on placebo. Detailed results were presented at the 86th ADA Scientific Sessions in June 2026 and feed directly into the retatrutide approval status page. Sources: Lilly investor release, TCTMD, AJMC.

TRIUMPH-2: Obesity with Type 2 Diabetes

TRIUMPH-2 evaluates retatrutide in people with obesity and type 2 diabetes — a population where the triple agonist mechanism is particularly relevant. The GIP receptor component enhances glucose-dependent insulin secretion, the GLP-1 component provides appetite suppression and additional glycemic control, and the glucagon component increases hepatic glucose output regulation and energy expenditure.

Lilly reported TRIUMPH-2 topline results on July 23, 2026: mean weight reductions of 12.7%, 19.1%, and 20.8% across the 4 mg, 9 mg, and 12 mg arms, with A1C reductions up to 1.6 percentage points. Full presentation or publication remains pending.

TRIUMPH-3: Severe Obesity With Established Cardiovascular Disease

TRIUMPH-3 was an 80-week Phase 3 obesity trial enrolling 1,949 adults with severe obesity and established cardiovascular disease. Lilly’s July 23 topline release reported up to 22.6% mean weight reduction. The release did not present TRIUMPH-3 as a completed MACE cardiovascular-outcomes trial, so this page does not claim a cardiovascular-event benefit.

Detailed TRIUMPH-3 results remain pending presentation or publication. The company-reported topline result is an obesity endpoint in a cardiovascular-disease population and must not be converted into a claim that retatrutide reduces MACE, mortality, or renal outcomes.

TRIUMPH-6: Weight Maintenance

TRIUMPH-6 addresses a critical question for any obesity drug: what happens when treatment is discontinued or reduced? The trial evaluates weight maintenance strategies, including dose reduction and treatment withdrawal. Specifically, it is assessing the effectiveness of a maintenance dose and the identification of a target dose to sustain weight loss over time, considering both clinical tolerability and long-term management.

Weight regain after discontinuation has been a significant concern across the GLP-1 class. Semaglutide’s STEP 4 trial showed rapid weight regain upon treatment withdrawal. If TRIUMPH-6 demonstrates durable weight maintenance with a reduced dose or after a defined treatment period, it would address one of the biggest clinical and commercial questions facing the obesity drug category — a finding that would also reshape the retatrutide dosage guide recommendations.

Phase 2 Data: What We Already Know

The Phase 2 trial (published in The New England Journal of Medicine, 2023) established retatrutide as the most potent weight-loss compound in clinical development. At the highest dose (12 mg), participants lost 24.2% of body weight at 48 weeks — and the weight-loss curves had not plateaued, suggesting further reductions would occur with longer treatment.

Fatty Liver / MASLD: Emerging TRIUMPH Data

Fatty liver disease, now commonly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is a growing concern among individuals with obesity and related metabolic disorders. Characterized by the accumulation of fat in the liver, MASLD is closely linked to insulin resistance, cardiovascular risk, and chronic kidney disease. Until recently, research options for fatty liver disease have been limited, especially when looking for compounds that address both liver fat content and significant weight loss in parallel.

Emerging data from the TRIUMPH clinical trial program highlight retatrutide’s potential to address this unmet need. In addition to delivering significant weight loss, retatrutide has demonstrated meaningful reductions in liver fat content — a key marker of improvement in associated steatotic liver disease. This effect is attributed to retatrutide’s activation of the glucagon receptor, which promotes hepatic fat oxidation, distinguishing it from other GLP-1 or dual agonist therapies.

The next step for these liver findings is a dedicated outcomes trial. SYNERGY-Outcomes (ClinicalTrials.gov NCT07165028) is a Phase 3 master protocol sponsored by Eli Lilly enrolling an estimated 4,500 adults with metabolic dysfunction-associated steatotic liver disease at increased risk of major adverse liver outcomes. It randomises both retatrutide (LY3437943) and tirzepatide against matched placebo, began in October 2025, and has primary completion estimated for August 2030. Retatrutide’s glucagon-receptor agonism — the same mechanism linked to the liver-fat reductions described above — is what distinguishes its arm from the dual-agonist comparator in this protocol.

The implications of these findings are substantial. By improving liver-fat metrics alongside body weight reduction, retatrutide may inform research models that link cardiovascular risk and renal outcomes in metabolic dysfunction. These benefits, observed in clinical trials, suggest that retatrutide could become a focal point of comprehensive weight-loss research datasets, especially in populations with fatty liver disease.

As research continues, the integration of investigational compounds like retatrutide with broader metabolic-health datasets will be essential for refining trial design. The TRIUMPH program’s results reinforce the promise of innovative compounds that address not only weight loss but also the broader spectrum of metabolic-health endpoints relevant to adults with obesity.

Safety Signals: What the Phase 3 Data Show

TRIUMPH-1 Phase 3 tolerability (May 21, 2026) is now the headline safety dataset. AE-driven discontinuation rose with dose: 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg vs 4.9% on placebo. That puts the 12 mg discontinuation rate above tirzepatide (approximately 5–7% in SURMOUNT trials) and semaglutide (approximately 6–7% in STEP trials), but well below the 18.2% seen with the older Phase 2 titration schedule — the optimised 2 mg start with 4-week steps materially improved tolerability.

Two Phase 3 signals merit attention. Dysesthesia — skin tingling/altered sensation — was reported in up to 12.5% of participants on 12 mg, higher than placebo and consistent with the TRIUMPH-4 signal flagged earlier. Urinary tract infections occurred in 7.5%, 8.8%, and 8.4% of the 4, 9, and 12 mg groups versus 5.3% on placebo. Lilly described these events as generally mild to moderate, with most resolving during treatment.

The most common adverse events remained gastrointestinal: nausea, diarrhea, vomiting, and decreased appetite, concentrated in the dose-escalation window and decreasing in severity over time. No unexpected safety signals outside the incretin class were identified.

Detailed TRIUMPH-1 results were presented at the 86th ADA Scientific Sessions in June 2026. For dose-by-dose AE rates across all retatrutide trials, see our retatrutide side effects guide.

How TRIUMPH Feeds the Approval Timeline

Eli Lilly plans a U.S. Biologics License Application in Q1 2027 after completing the chemistry, manufacturing, and controls package. No application has yet been approved. The cross-asset comparison here is moving fast — the recently approved oral candidate is covered in Foundayo (orforglipron) FDA approval.

If a filing follows the remaining TRIUMPH readouts, a standard 10–12-month FDA review cycle would put any decision at least a year after that — outside analyst projections for a launch range from 2027 into 2028. Priority Review designation, if granted, could shorten the review by several months. This section is here to show how the trial sequence feeds that path, not to replace the direct status answer.

Key milestones to watch: TRIUMPH-1 readout (2026), TRIUMPH-2 readout (2026), NDA submission announcement, and FDA acceptance of the filing. Track all pipeline milestones on our obesity drug approval tracker, browse the full index of obesity-drug approval trackers, and use the retatrutide status page for the current regulatory position.

July 23, 2026 TRIUMPH-2 and TRIUMPH-3 update

Eli Lilly reported topline results from two additional Phase 3 retatrutide trials on July 23, 2026. In TRIUMPH-2 (1,152 adults with obesity or overweight and type 2 diabetes; 80 weeks), the company reported mean weight reductions of 12.7% at 4 mg, 19.1% at 9 mg, and 20.8% at 12 mg, with A1C reductions up to 1.6 percentage points. In TRIUMPH-3 (1,949 adults with severe obesity and established cardiovascular disease; 80 weeks), mean weight reduction reached 22.6%. These are company-reported topline findings pending full presentation or publication, not a head-to-head comparison.

Lilly also stated that it plans a U.S. Biologics License Application in Q1 2027 after completing the chemistry, manufacturing, and controls package. Retatrutide remains investigational and no application has yet been approved. Primary source: Eli Lilly, July 23, 2026.